Expanded Access Program for Revumenib

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Syndax Pharmaceuticals
Study ID
NCT05918913
Status
No Longer Available

Conditions

  • Relapsed/Refractory Acute Leukemia

Eligibility Criteria

Sex
ALL
Age
6 Months - N/A
Healthy Volunteers
Not accepted

Interventions

  • Revumenib — DRUG
    Revumenib administered orally every 12 hours.

Study Details

This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.

Key Dates

Status verified
Aug 2025

Locations (35)

FacilityCityStateZIPSite coordinators
Alabama Center for Childhood Cancer And Blood Disorders, Children's of AlabamaBirminghamAlabama35233-
Phoenix Children's HospitalPhoenixArizona85016-
City of HopeDuarteCalifornia91010-
City of Hope at Orange County Lennar Foundation Cancer CenterIrvineCalifornia92618-
UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply ShipmentLos AngelesCalifornia90095-
Lucile Packard Children's Hospital-StanfordPalo AltoCalifornia94304-
Rady Children's HospitalSan DiegoCalifornia92123-
University of California, San FranciscoSan FranciscoCalifornia94158-
Center for Cancer and Blood Disorders, Colorado Children's HospitalAuroraColorado80045-
HCTU, Division of Hematology, University of Colorado, Anschutz Medical CenterAuroraColorado80045-
Advent Health OrlandoOrlandoFlorida32804-
Children's Healthcare of AtlantaAtlantaGeorgia30322-
Winship Cancer Institute at Emory UniversityAtlantaGeorgia30322-
Lurie Children's Hospital of ChicagoChicagoIllinois60611-
University of Chicago Medical CenterChicagoIllinois60637-
University of Iowa Hospitals and ClinicsIowa CityIowa52242-
Children's HospitalNew OrleansLouisiana70118-
Dana-Farber Cancer Institute, Boston Children's Cancer and Blood Disorders CenterBostonMassachusetts02215-
Children's Mercy Hospital-Kansas CityKansas CityMissouri64108-
Siteman Cancer Center - Washington UniversitySt LouisMissouri63110-
Hackensack University Medical CenterHackensackNew Jersey07601-
Memorial Sloan Kettering Cancer CenterLong Island CityNew York10065-
Montefiore Medical CenterThe BronxNew York10467-
Duke University Medical CenterDurhamNorth Carolina27705-
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229-
Division of Hematology and Oncology, Division of Pulmonary, Critical Care and Sleep Medicine, Vontz Center for Molecular StudiesCincinnatiOhio45267-
OSU Medical CenterColumbusOhio43210-
Doernbecher Children's Hospital, Oregon Health & Science UniversityPortlandOregon97239-
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104-
St. Jude Children's Research HospitalMemphisTennessee38105-
MD Anderson Cancer CenterHoustonTexas77030-
Memorial Hermann-Texas Medical CenterHoustonTexas77030-
Texas Children's HospitalHoustonTexas77030-
Division of Hematology and Hematologic Malignancies, University of Utah-Huntsman Cancer HospitalSalt Lake CityUtah84112-
Seattle Children's Research Institute, Seattle Childrens HospitalSeattleWashington98105-

Find similar trials in Birmingham, AL